This compound is primarily utilized in the development of targeted cancer therapies. It functions as a linker in antibody-drug conjugates (ADCs), enabling the precise delivery of cytotoxic agents to cancer cells while minimizing damage to healthy tissues. The inclusion of thalidomide allows for additional modulation of protein degradation, particularly in targeting specific proteins involved in cancer progression. Its PEG2 spacer enhances solubility and stability, improving the pharmacokinetic properties of the conjugate. This makes it a valuable tool in advancing personalized medicine and improving the efficacy of cancer treatments.